Every Form 4 that AC Immune SA (ACIU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACIU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACIU filings page.
AC Immune SA director Roy Ervin Twyman received equity awards as compensation. On June 11, 2026 he was granted 16,568 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan, increasing his holdings to 92,556 common shares, including 66,556 shares underlying outstanding restricted share units.
On the same date he also received share options over 38,889 common shares with an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036, giving him the right to buy the underlying shares in the future rather than reflecting an open-market purchase.
AC Immune SA director Renee Aguiar-Lucander reported equity compensation awards rather than open-market trades. On June 11, 2026, she received a restricted share unit grant covering 16,568 common shares under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this grant, 51,136 common shares are underlying her outstanding restricted share units. She was also awarded options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036.
AC Immune SA interim CEO Martin Zuegel reported equity compensation awards. On June 11, 2026, he received a grant of 33,136 restricted share units under the company’s 2016 Stock Option and Incentive Plan. Following this award, he holds 71,408 common shares underlying outstanding restricted share units.
On the same date, he was also granted share options on 77,778 common shares at an exercise price of $2.6200 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. All reported holdings are direct.
AC Immune SA director Monika Buetler received new equity awards as part of her compensation. On June 11, 2026, she was granted 17,751 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan. The grant increases her direct interest in the company without any cash purchase.
On the same date, she also received share options for 41,667 common shares at an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. After these awards, she directly holds 71,656 common shares, largely reflecting restricted share units rather than open-market buying.
AC Immune SA director June Carl Howard reported new equity compensation grants. On June 11, 2026, she received 16,568 common shares as a restricted share unit grant under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this award, her direct holdings in common shares were 67,556. She also received share options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036. These awards reflect compensation rather than open‑market trading.
AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market sale of 10,000 common shares. The trade occurred on May 15, 2026 at a weighted average price of $2.7935 per share, with individual prices ranging from $2.75 to $2.825.
After this sale, Pfeifer directly holds 3,820,288 common shares, which include 1,921,005 common shares underlying outstanding restricted share units. She also reports 14,000 common shares held indirectly by her spouse.
AC Immune SA Chief Executive Officer Andrea Pfeifer sold 10,000 shares of the company’s stock in an open-market transaction. The amended filing clarifies that a prior report mistakenly showed this activity as a purchase and now correctly records it as a sale.
The shares were sold at a weighted average price of $3.1425, with individual trade prices ranging from $3.05 to $3.19. After the sale, Pfeifer directly owns 3,830,288 shares, including 1,921,005 common shares underlying outstanding restricted share units, and also has indirect ownership of 14,000 shares held by her spouse.
AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market purchase of 10,000 common shares on April 15, 2026 at a weighted average price of $3.1425 per share, with individual trades ranging from $3.05 to $3.19.
Following this transaction, she directly owns 3,830,288 shares, which include 1,921,005 common shares underlying outstanding restricted share units. In addition, 14,000 shares are reported as indirectly owned through her spouse.